Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase II study of nilotinib-based induction and consolidation therapy in elderly Ph+ acute lymphoblastic leukemia
2010-022855-46Phase 2Completed
- Sponsor
- Goethe University Frankfurt
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nilotinib in acute lymphoblastic leukemia (ALL), sponsored by Goethe University Frankfurt. Primary endpoint: Rate of patients without event at 12 months. Started Jun 2011; status: completed.
02
Drugs
nilotinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2010-022855-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022855-46.